¹Ì±¹ FDA cGMP ´ëÀÀ½Ç¹« (19³â1Â÷)
80% | 20% |
ÀÌ·Ð | ½Ç½À |
1. °ú Á¤ ¸í : ¹Ì±¹ FDA cGMP ´ëÀÀ ½Ç¹«
ÀÏ ÀÚ |
½Ã °£ |
±³À°³»¿ë |
1ÀÏÂ÷ |
09:30~10:30 |
¡Û ¹Ì±¹ cGMP inspection ÇÁ·Î¼¼½º - 21 CFR Part820-Management control |
10:30~11:30 |
||
11:30~£±2:30 |
Áᫎ |
|
12:30~13:30 |
¡Û ¹Ì±¹ cGMP inspection ÇÁ·Î¼¼½º - 21 CFR Part820-Management control |
|
13:30~14:30 |
¡Û ¹Ì±¹ cGMP inspection ÇÁ·Î¼¼½º - 21 CFR Part820-Corrective and Preventive Actions |
|
14:30~15:30 |
||
15:30~16:30 |
¡Û ¹Ì±¹ cGMP inspection ÇÁ·Î¼¼½º - 21 CFR Part820-Corrective and Process Controls |
|
16:30~17:30 |
||
2ÀÏÂ÷ |
09:30~10:30 |
¡Û ¹Ì±¹ cGMP inspection ÇÁ·Î¼¼½º - 21 CFR Part820-Material Controls |
10:30~11:30 |
¡Û ¹Ì±¹ cGMP inspection ÇÁ·Î¼¼½º - 21 CFR Part820-Documents/REcords/Change Control |
|
11:30~12:30 |
Áᫎ |
|
12:30~13:30 |
¡Û ¹Ì±¹ eMDR µî·Ï ÇÁ·Î¼¼½º |
|
13:30~14:30 |
¡Û Á¦Ç°À̷±â·Ï(DHR)ÀÛ¼º »ç·Ê¿¬±¸ |
|
14:30~15:30 |
¡Û ¹Ì±¹ cGMP ÁöÀû»çÇ× »ç·Ê¿¬±¸ |
|
15:30~16:30 |
¡Û 483 Observation ÈļÓÁ¶Ä¡ »ç·Ê¿¬±¸ |
|
16:30~17:30 |
¡Ú ±³À°Àü Çʵ¶ ¾È³»»çÇ× ¡Ú
(1) ½Åû ´ë»ó : Á¶ÇÕ¿¡¼ ÁøÇàµÇ´Â ±³À°Àº Á¶ÇÕ°ú Çù¾àÀ» ü°áÇÑ Áß¼Ò±â¾÷ÀçÁ÷ÀÚ¸¦ ´ë»óÀ¸·Î ÇÏ´Â ±³À°À¸·Î
°í¿ë³ëµ¿º¸Çè¿¡ °¡ÀÔÇÑ Çù¾à±â¾÷ÀÇ ÀçÁ÷ÀÚ¸¸ ±³À° ¼ö°ÀÌ °¡´ÉÇÕ´Ï´Ù.
- Çù¾à±â¾÷È®ÀÎ : http://www.medihrd.or.kr/apply/partner_list.php (¸®½ºÆ®¿¡ ȸ»ç¸íÀÌ ÀÖÀ¸¸é Çù¾à±â¾÷ÀÔ´Ï´Ù.)
* Çù¾à±â¾÷¸®½ºÆ®¿¡ ȸ»ç¸íÀÌ ÀÖÀ¸¸é Çù¾à±â¾÷À̸ç, Á¶ÇÕȸ¿ø»ç ¿©ºÎ¿Í °ü°è¾øÀÌ ½Åû±³À° ¼ö·á½Ã ±³À°ºñ´Â ¹«·áÀÔ´Ï´Ù.
- Çù¾àü°á¾È³» : http://www.medihrd.or.kr/about/argeement.php(Çù¾àü°áÀº ¹«·áÀÔ´Ï´Ù.)
▸Áغñ¹° : Çʱ⵵±¸, °³ÀγëÆ®ºÏ (2ÀÏÂ÷ °øÁ¤´É·Â½Ã°£¿¡ ¿¢¼¿·Î °è»ê ±³À° ÁøÇà ¿¹Á¤)
- ±³À°±â°£ Áß ÁÖÂ÷°¡ ºÒ°¡ÇÕ´Ï´Ù. ´ëÁß±³ÅëÀ» ÀÌ¿ëÇÏ¿© ±³À°¿¡ Âü¼®ÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.